{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:44:57Z","timestamp":1780433097856,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.04.085","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T20:04:31Z","timestamp":1496261071000},"page":"4461-4464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"PA","title":["Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology"],"prefix":"10.1016","volume":"35","author":[{"given":"Sarah C.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Warimwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.085_b0005","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1016\/j.vaccine.2016.07.028","article-title":"Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors","volume":"34","author":"Herath","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.085_b0010","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.085_b0015","first-page":"77","article-title":"Emerging and reemerging of filoviruses","volume":"11","author":"Feldmann","year":"1996","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.vaccine.2017.04.085_b0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2017.04.085_b0025","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.085_b0030","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.04.085_b0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.085_b0040","doi-asserted-by":"crossref","unstructured":"Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115ra1.","DOI":"10.1126\/scitranslmed.3003155"},{"key":"10.1016\/j.vaccine.2017.04.085_b0045","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - preliminary report","author":"Agnandji","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.085_b0050","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.085_b0055","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.04.085_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.085_b0065","first-page":"65","article-title":"Rift valley fever","volume":"10","author":"Easterday","year":"1965","journal-title":"Adv Veterin Sci"},{"key":"10.1016\/j.vaccine.2017.04.085_b0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","article-title":"Rift Valley fever: an emerging mosquito-borne disease","volume":"61","author":"Linthicum","year":"2016","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2017.04.085_b0075","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic Hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.vaccine.2017.04.085_b0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","article-title":"Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007","volume":"83","author":"Mohamed","year":"2010","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2017.04.085_b0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clinic Infect Diseases: an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.vaccine.2017.04.085_b0090","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1016\/S2214-109X(16)30176-0","article-title":"Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study","volume":"4","author":"Baudin","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2017.04.085_b0095","first-page":"61","article-title":"Vaccination for the control of Rift Valley fever in enzootic and epizootic situations","volume":"135","author":"Dungu","year":"2013","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2017.04.085_b0100","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee Adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.04.085_b0105","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.085_b0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid2004.131746","article-title":"Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013","volume":"20","author":"Meyer","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.085_b0115","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3201\/eid2008.140590","article-title":"Geographic distribution of MERS coronavirus among dromedary camels, Africa","volume":"20","author":"Reusken","year":"2014","journal-title":"Emerg Infect Diseases"},{"key":"10.1016\/j.vaccine.2017.04.085_b0120","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1128\/JVI.00676-14","article-title":"Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4","volume":"88","author":"van Doremalen","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.085_b0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/path.4458","article-title":"Pathogenesis of Middle East respiratory syndrome coronavirus","volume":"235","author":"van den Brand","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2017.04.085_b0130","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3201\/eid2108.150481","article-title":"Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013\u20132014","volume":"21","author":"Reusken","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.085_b0135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(15)70090-3","article-title":"Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study","volume":"15","author":"Muller","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.085_b0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","article-title":"An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels","volume":"351","author":"Haagmans","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.085_b0145","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T08:40:38Z","timestamp":1535791238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":29,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17306011"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}